Latest episode
1. Season 2 premiere! CLL and Richter's Transformation with Dr. Adam Kittai
58:07||Season 2, Ep. 1Dr. Adam Kittai joins us to discuss the role for cellular therapy and allogeneic transplantation in the treatment of chronic lymphocytic leukemia and Richter's transformation. We discuss his recent publication in JCO "Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation", the approval of liso-cel for CLL, and more!
More episodes
View all episodes
6. Episode 6 - Thinking Meta about CAR Mortality with David Cordas dos Santos and Kai Rejeski
53:59||Season 1, Ep. 6We chat with David Cordas dos Santos and Kai Rejeski, first and last author of a major new article in Nature Medicine:A Systematic Review and Metaanalysis of Nonrelapse Mortality after CAR T Cell Therapy.5. Episode 5 - Transplant Strikes Back... immediately! The ASAP trial takes on active disease
01:18:20||Season 1, Ep. 5We were delighted to speak with Dr. Arjun Law (Princess Margaret Cancer Center, Toronto, ON) about the ASAP trial https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00065-6/fulltext (Stelljes, Middeke, Bug et al., Lancet Haem 2024) and his thoughtful commentary https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00072-3/fulltext (Law, Mattsson, Lancet Haem 2024).4. To p(53) or not to p(53): interview with Dr. Mariam Nawas
54:46||Season 1, Ep. 4What a delight to have Dr. Mariam Nawas of the University of Chicago join us for a round-up of her favorite abstracts from Tandem 2024! We also discussed her recent and controversial review "Utility or futility? A contemporary approach to allogeneic hematopoietic cell transplantation for TP53-mutated MDS/AML", which appeared in Blood Advances earlier this year.
3. CARpe diem! Lymphoma CAR-T roundup with Dr. Sam Yamshon
01:02:40||Season 1, Ep. 3Dr. Sam Yamshon, assistant professor of medicine at Weill Cornell Medicine at New York Presbyterian, joins us to chat about the most thought-provoking lymphoma CAR-T abstracts from #Tandem24.
2. ICAHT Take It Anymore!
01:02:16||Season 1, Ep. 2We're joined 'in the studio' by our very first interview guest, our good friend, the brilliant Dr. Kai Rejeski. Kai has been at the forefront of understanding hematologic toxicity of CAR-T therapies, and speaks with us about the HEMATOTOX score, ICAHT guidelines, and the excellent coffee in San Antonio.
1. Episode 1! Off to Tandem 24
23:55||Season 1, Ep. 1Welcome! This is the first episode of Chimerically Speaking. We're excited to share our love for the science and brilliant, creative community of transplantation and cellular therapy. In this episode we'll talk about the upcoming Tandem 2024 meeting ahead of traveling to San Antonio this week. We highlight two abstracts (of so many!) that really caught our attention:Al Malki and colleages, TSC-100/TSC-101 Ph. 1 https://tandem.confex.com/tandem/2024/meetingapp.cgi/Paper/23846Schoettler and colleagues, TA-TMA and age https://tandem.confex.com/tandem/2024/meetingapp.cgi/Paper/22981